Thymosin alpha-1, also called thymalfasin, is a thymic peptide studied for immune modulation. Human clinical research includes people with chronic hepatitis B, where investigators measured disease-specific treatment responses.
Research focus: Immune responses in disease-specific research.
Choose a compound to open its research, documentation and calculator.
No FDA-approved drug product for this catalog material. Compounding eligibility and approval are separate questions.
Official source ↗Nine healthy volunteers; formulation affected the pharmacokinetic measurements.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗PeptIQ lists bacteriostatic water for repeated-vial workflows. That preference is not a compatibility study for a particular formulation; the actual product or pharmacy instructions determine the liquid.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗A regimen studied for hepatitis B is not a general immune-support regimen. Approval and prescribing information must be checked for the specific product and country.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Disease-specific human studies; product approval and indications vary by country.
Other names you may encounter: Thymalfasin, TA1.
Learn to read a study →Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
The longer duration belongs to a chronic-condition discussion, rather than a general wellness cycle.
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
Choose activity that fits your health and ability. Aerobic movement and muscle-strengthening work are part of general adult activity guidance.
CDC · adult activity ↗Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Follow the care plan for the actual condition. Record symptoms and concurrent treatment so a change can be interpreted in context.
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.
Estimate · assumes 1 mL added = total volume
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
Illustration only · calculated value, without rounding
Saved calculations stay on this device.
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
5units
0.05 mL · 0.25 mg
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
1,000mcg
For mass → syringe volume, switch to Dosage and enter a concentration.